The Filing Desk

Myriad Genetics

MYGN · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

MYGN · Last close · November 13, 2026
$5.66
Value Myriad Genetics yourself

Myriad Genetics' revenue fell 1.6% to $824 million in fiscal 2025. Its operating margin was −47.0%, down from −14.7% a year earlier. Free cash flow was −$14 million. The diluted share count rose 2.2%.

MYRIAD GENETICS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 24, 2026 · 0000899923-26-000018 Updated
Revenue
$824M
1.6%
Operating margin
−47.0%
32.2 pts
Net income
−$366M
 
Free cash flow
−$14M
 
Return on capital
−62.6%
47.9 pts
Market cap
$542M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Myriad Genetics does

Myriad Genetics develops and sells molecular tests that read a person's DNA or tumor for genetic information. The tests assess the risk of developing a disease or how it may progress, and help guide treatment. It works across three areas: cancer care, prenatal health and mental health.

In cancer, it offers hereditary cancer testing that covers eleven common cancer types, including breast, ovarian, colorectal, prostate, lung and skin. It also sells a test called HRD, used to choose cancer therapy, and Precise MRD, which looks for small amounts of cancer remaining after treatment. The company says it plans to add more comprehensive tumor profiling tests through its own development and partnerships.

Myriad says it aims to grow its prenatal and mental health revenue at or above market growth, and to expand its tests across cancer care. It sells mostly through its commercial reach in community medicine, serving doctors and patients. Its revenue depends on insurers and government payers covering and paying for its tests.

Its biggest risks, as it describes them

  • It may not be able to earn enough from its existing tests or develop new ones to be profitable.
  • Its strategic plan may not deliver the expected results or revenue growth.
  • If government and other payers do not cover its tests and pay enough, its revenue will suffer.
  • Its debt covenants limit its operations and finances, and it may need more funding.
  • It has faced securities class actions and shareholder suits, and may face product or professional liability claims.
From Myriad Genetics's annual report on Form 10-K, filed February 24, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2019, earnings per share fell 66.5% a year and net income 66.0% a year, as new shares raised the share count by 4% and diluted each share's earnings. Myriad Genetics then lost money in fiscal 2020, 2021, 2022, 2023, 2024 and 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments399170141102150
Debt incl. finance leases003840120
Net debt (negative means net cash)−399−170−102−63−30
Net debt to EBITDA—————
Debt to equity0.0x0.0x0.1x0.1x0.3x
Interest coverage−28.9x−43.9x−88.8x−44.1x−36.9x
Current ratio2.4x2.0x2.0x1.8x2.5x
Quick ratio2.3x1.9x1.9x1.6x2.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Myriad Genetics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Myriad Genetics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 94 of 95 of 9
Rule of 40−12.1%7.9%−3.2%
Altman Z''−0.13−0.10−5.88
Accruals ratio−13.0%−10.9%−42.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailPass
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsPassPassPass
F-score3 of 94 of 95 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Myriad Genetics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Myriad GeneticsFY25−1.6%−47.0%−1.7%−62.6%—5
NeoGenomics LaboratoriesFY2510.1%−15.9%−3.0%−8.8%—5Compare
Pennant GroupFY2536.3%5.5%3.8%9.3%2.6x5Compare
CorVelFY267.0%—11.5%———Compare
Sotera HealthFY255.7%—12.8%6.7%—7Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue754771744851639691678753838824
Revenue growth4.2%2.3%−3.6%14.4%−25.0%8.1%−1.8%11.0%11.2%−1.6%
Gross profit621626————476517585577
Research and development7174718677828589113107
Operating income153441228−232−190−141−257−124−387
Net income117171335−200−27−112−263−127−366
Diluted EPS (US$)1.600.251.850.06−2.69−0.35−1.39−3.18−1.41−3.95
Diluted shares (millions)73697276747881839193
Cash flow
Cash from operations166106116846119−106−111−92
Capital expenditure5689101845631916
Free cash flow16110010875501−152−174−28−14
Dividends paid0000000000
Share buybacks16332050000000
Acquisitions3721602780057000
Stock-based compensation32302734253638415035
Balance sheet at fiscal year end
Cash and short-term investments159151181192255399170141102150
Debt incl. finance leases—999234224003840120
Total assets8801,2091,1751,5631,4051,3211,1991,1461,028707
Total liabilities132441209474486353313363326339
Shareholders' equity7407689661,089918968886783701368
Margins and ratios
Gross margin82.4%81.2%————70.2%68.6%69.9%69.9%
Operating margin20.4%5.7%16.4%0.9%−36.3%−27.6%−20.7%−34.2%−14.7%−47.0%
Net margin15.6%2.3%17.9%0.5%−31.2%−3.9%−16.5%−35.0%−15.2%−44.4%
Free cash flow margin21.4%13.0%14.4%8.8%7.9%0.1%−22.4%−23.1%−3.3%−1.7%
Rule of 40 (growth + FCF margin)25.6%15.3%10.9%23.3%−17.1%8.2%−24.1%−12.1%7.9%−3.2%
Return on capital——16.1%0.6%−18.1%−20.7%−17.3%−29.1%−14.8%−62.6%
Return on equity16.7%2.3%15.4%0.5%−19.9%−2.9%−12.1%−31.6%−17.1%−68.5%
Return on assets14.2%1.7%11.2%0.3%−13.4%−2.0%−8.9%−22.4%−11.7%−42.2%
Net debt to EBITDA—−0.6x−1.0x0.5x——————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Myriad Genetics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Myriad Genetics.